Aktiechat - investeringstips
Aktiesnakken
Genmab
Gubra
Bavarian Nordic
TESLA
NOVO
Zealand Pharma
Chemometec
Biotek-snakken
Amerikanske aktier
AI/Kunstig intelligens
Ennogie
Maersk
AMBU
ExpreS2ion
Pharma
Banker og Finans
EL-BILER
Grønne Aktier
Vestas
GN Store Nord
Laks
Shipping
Smallcap og First North aktier
Danske Bank
Hansa Biopharma
Medico
BITCOIN
Krypto
OLIE OG GAS
11/11 15:05 af Jan Van de Winkel |
but we do think the immunomodulatory activity may very well turn out to be very impactful and lead to a potential broader target population for the antibody.
| |
11/11 15:04 af Jan Van de Winkel |
It is not easy to attribute efficacy in patients to a particular mechanism of action....
| |
11/11 15:04 af Jan Van de Winkel |
Daratumumab is unique in having such a broad set of mechanisms of action, this has not been seen before with any other antibody...
.
| |
11/11 15:03 af Sukkeralf |
Looking at daratumumabs 5-6 mechanism of action - is it kind of possible to rank the importance of them ?. And especially the new possible immunomodulatory effect - if thats for real how much do you think that could impact the current peaksale predictions ($5-6 billion) ?
| |
11/11 15:03 af Helge Larsen/PI-redaktør |
And now some questions about Dara.
| |
11/11 15:02 af Jan Van de Winkel |
Financials, we improved the operating results by 74% vs same time in 2014, and improved our 2015 full year financial guidance.
| |
11/11 15:01 af Jan Van de Winkel |
We got priority review for ofa CLL maintenance in the US, and we also signed a DuoBody platform commercial deal with Novo Nordisk....
| |
11/11 15:01 af Jan Van de Winkel |
In the third quarter we filed dara in both the US and the EU, and got priority review in the US and accelerated assessment in the EU (in September), ...
| |
11/11 15:00 af Helge Larsen/PI-redaktør |
Let's start. Can you give a short-term update on key figures and important events in the third quarter?
| |
11/11 14:59 af Jan Van de Winkel |
We are delighted to be chatting with you again....
| |
11/11 14:58 af Helge Larsen/PI-redaktør |
Welcome to the Q & A here on the ProInvestor, Jan and David
and congrats for a good quater. We are very happy that you are back here and ready to answer questions from our investors
| |
11/11 14:58 af Jan Van de Winkel |
Yes I am here with David Eatwell our CFO. Nice to be with you again.
| |
11/11 14:57 af Helge Larsen/PI-redaktør |
Are you with us here online Jan?
| |
11/11 14:48 af Helge Larsen/PI-redaktør |
In 10 minutes we begin the online Q&A with Genmab.
|